Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
N Engl J Med ; 376(12): 1141-1146, 2017 03 23.
Artigo em Inglês | MEDLINE | ID: mdl-28328326

RESUMO

A patient with leukocyte adhesion deficiency type 1 (LAD1) had severe periodontitis and an intractable, deep, nonhealing sacral wound. We had previously found a dominant interleukin-23-interleukin-17 signature at inflamed sites in humans with LAD1 and in mouse models of the disorder. Blockade of this pathway in mouse models has resulted in resolution of the immunopathologic condition. We treated our patient with ustekinumab, an antibody that binds the p40 subunit of interleukin-23 and interleukin-12 and thereby blocks the activity of these cytokines, inhibiting interleukin-23-dependent production of interleukin-17. After 1 year of therapy, our patient had resolution of his inflammatory lesions without serious infections or adverse reactions. Inhibition of interleukin-23 and interleukin-17 may have a role in the management of LAD1. (Funded by the National Institute of Allergy and Infectious Diseases and others.).


Assuntos
Interleucina-12/antagonistas & inibidores , Interleucina-23/antagonistas & inibidores , Síndrome da Aderência Leucocítica Deficitária/tratamento farmacológico , Ustekinumab/uso terapêutico , Gengiva/patologia , Humanos , Injeções Subcutâneas , Interleucina-17/metabolismo , Interleucina-23/metabolismo , Síndrome da Aderência Leucocítica Deficitária/complicações , Masculino , Doenças Periodontais/tratamento farmacológico , Doenças Periodontais/etiologia , Doenças Periodontais/patologia , RNA Mensageiro/metabolismo , Úlcera Cutânea/tratamento farmacológico , Úlcera Cutânea/etiologia , Úlcera Cutânea/patologia , Ustekinumab/efeitos adversos , Adulto Jovem
2.
Tissue Eng ; 12(10): 2939-48, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17518661

RESUMO

There is no satisfactory conventional treatment for patients who experience irreversible salivary gland damage after therapeutic radiation for head and neck cancer or because of Sjögren's syndrome. Additionally, if most parenchyma is lost, these patients also are not candidates for evolving gene transfer strategies. To help such patients, several years ago we began to develop an artificial salivary gland. In the present study, we used a non-human primate tissue source, parotid glands from rhesus monkeys, to obtain potential autologous graft cells for development of a prototype device for in situ testing. Herein, we present 3 major findings. First, we show that primary cultures of rhesus parotid gland (RPG) cells are capable of attaining a polarized orientation, with Na(+)/K(+)-adenosine triphosphatase, zonula occludens-1, and claudin-1 distributed in specific domains appropriate for epithelial cells. Second, we show that RPG cells exhibit 2 essential epithelial functions required for graft cells in an artificial salivary gland device (i.e., an effective barrier to paracellular water flow and the generation of a moderate transepithelial electrical resistance). Third, we show that RPG cells can express functional water channels, capable of mediating directional fluid movement, after transduction by adenoviral and adeno-associated virus type 2 vectors. Together these results demonstrate that it is feasible to individually prepare RPG cells for eventual use in a prototype artificial salivary gland.


Assuntos
Bioprótese , Células Epiteliais/citologia , Técnicas de Cultura de Órgãos/métodos , Glândula Parótida/citologia , Glândulas Salivares/citologia , Glândulas Salivares/crescimento & desenvolvimento , Engenharia Tecidual/métodos , Animais , Diferenciação Celular , Proliferação de Células , Células Cultivadas , Células Epiteliais/fisiologia , Desenho de Equipamento , Análise de Falha de Equipamento , Macaca mulatta , Mucosa Bucal/citologia , Mucosa Bucal/fisiologia , Glândula Parótida/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA